Associate Professor Michelle Farrar and colleagues from Sydney Children’s Hospital (Randwick) are conducting a new research project to lean more about what factors are important when making decisions related to treatment for spinal muscular atrophy (SMA). They are seeking the views of parents/carers of people with SMA, health care providers and the wider community. Please find attached more […]
Recruitment Request: Understanding patients’ and carers’ decision making in Spinal Muscular Atrophy Care
Read full story • Comments are closed
Lifeline for Pompe disease patients
RCH clinicians have worked with the Australian Pompe Association, drug company Genzyme and the Federal government to achieve government-subsidised treatment for late-onset Pompe disease. 12-year-old patient Christian Rivera received his first infusion at the RCH last week. The federal government has listed the only registered treatment for Pompe disease, Myozyme (alglucosidase alfa), on the Life […]
Read full story • Comments are closed
Development of Allied Health and Nursing Best Practice Guidelines for Duchenne muscular dystrophy
The development of the Duchenne muscular dystrophy clinical practice guideline is currently underway utilising an NHMRC guided process. In keeping with this process, a call for committee members to join the scientific steering group is now open. We would welcome your participation. The guideline development process involves a number of steps. As a snapshot, the […]
Read full story • Comments are closed
Allied Health and Nursing Alliance (AHNA)
The Allied Health and Nursing Alliance (AHNA) has now been established! We are seeking new members to join our dynamic team to work towards providing one Australasian voice for the Allied Health and Nursing care and research of patients with neuromuscular disorders. Please visit our AHNA webpage for further details: http://www.ann.org.au/allied-health-and-nursing-alliance-ahna/.
Read full story • Comments are closed
ANN Congress 2021 – Save the Date
The annual ANN Congress will be on Friday 8th October 2021 at the Larwill Hotel in Melbourne. This will be an in-person congress with numbers strictly limited to 60 attendess. It will be simultaneously streamed by webinar for those unable to attend in person. Draft programme to follow… Registrations will open in August.
Read full story • Comments are closed
Charcot-Marie-Tooth Clinical Outcome Measure Update
Professor Joshua Burns has launched an updated web-based tool too assist researchers and clinicians to measure the level of disability in Charcot-Marie-Tooth disease (CMT). This new website enables users to rapidly score clinical outcome measures including: the Charcot-Marie-Tooth disease Pediatric Scale (CMTPedS), CMT Infant Scale (CMTInfs), CMT Functional Outcome Measure (CMT-FOM), CMT Neuropathy Score (CMTNS) […]
Read full story • Comments are closed
Early Access Program for Nusinersen
Early Access Program for Nusinersen There has been a lot of activity in the clinical trial space for the treatment of Spinal Muscular Atrophy (SMA) over the last two years, and Nusinersen, has been identified as the first effective drug to treat SMA Type 1. Developed in California, Nusinersen (know in the USA […]
Read full story • Comments are closed